The future is now-prospective study of radiosurgery for more than 4 brain metastases to start in 2018!

David Roberge, Paul D. Brown, Anthony Whitton, Chris O'Callaghan, Anne Leis, Jeffrey Greenspoon, Grace Li Smith, Jennifer Hu, Alan Nichol, Chad Winch, Michael D. Chan

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Stereotactic radiosurgery (SRS) has replaced whole brain radiotherapy (WBRT) as standard therapy for most patients with four or fewer brain metastases due to improved cognitive outcomes and more favorable health related quality of life (QoL). Whether SRS or WBRT is the optimal radiation modality for patients with five to fifteen brain metastases remains an open question. Efforts are underway to develop prospective evidence to answer this question. One of the planned trials is a Canadian Cancer Trials Group (CCTG)-lead North American intergroup trial. In general cancer treatments must have two basic aims: prolonging and improving QoL. In this vein, the selection of overall survival and QoL metrics as outcomes appear obvious. Potential secondary outcomes are numerous: patient/disease related, treatment related, economic, translational, imaging, and dosimetric. In designing a trial, one must also ponder what is standard WBRT-specifically, whether it should be associated with memantine. With the rapid accrual of an intergroup trial of hippocampal-sparing WBRT, we may find that the standard WBRT regimen changes in the course of planned trials. As up-front radiosurgery is increasingly used for more than 4 brain metastases without high level evidence, we have a window of opportunity to develop high quality evidence which will help guide our future clinical and policy decisions.

Original languageEnglish (US)
Article number380
JournalFrontiers in Oncology
Volume8
Issue numberSEP
DOIs
StatePublished - Sep 13 2018

Fingerprint

Radiosurgery
Prospective Studies
Neoplasm Metastasis
Brain
Radiotherapy
Quality of Life
Memantine
Veins
Neoplasms
Therapeutics
Economics
Radiation
Survival

Keywords

  • Brain metastasis
  • Clinical trials
  • Neurocognition
  • Phase III as topic
  • Radiosurgery
  • Whole brain radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Roberge, D., Brown, P. D., Whitton, A., O'Callaghan, C., Leis, A., Greenspoon, J., ... Chan, M. D. (2018). The future is now-prospective study of radiosurgery for more than 4 brain metastases to start in 2018! Frontiers in Oncology, 8(SEP), [380]. https://doi.org/10.3389/fonc.2018.00380

The future is now-prospective study of radiosurgery for more than 4 brain metastases to start in 2018! / Roberge, David; Brown, Paul D.; Whitton, Anthony; O'Callaghan, Chris; Leis, Anne; Greenspoon, Jeffrey; Smith, Grace Li; Hu, Jennifer; Nichol, Alan; Winch, Chad; Chan, Michael D.

In: Frontiers in Oncology, Vol. 8, No. SEP, 380, 13.09.2018.

Research output: Contribution to journalReview article

Roberge, D, Brown, PD, Whitton, A, O'Callaghan, C, Leis, A, Greenspoon, J, Smith, GL, Hu, J, Nichol, A, Winch, C & Chan, MD 2018, 'The future is now-prospective study of radiosurgery for more than 4 brain metastases to start in 2018!', Frontiers in Oncology, vol. 8, no. SEP, 380. https://doi.org/10.3389/fonc.2018.00380
Roberge, David ; Brown, Paul D. ; Whitton, Anthony ; O'Callaghan, Chris ; Leis, Anne ; Greenspoon, Jeffrey ; Smith, Grace Li ; Hu, Jennifer ; Nichol, Alan ; Winch, Chad ; Chan, Michael D. / The future is now-prospective study of radiosurgery for more than 4 brain metastases to start in 2018!. In: Frontiers in Oncology. 2018 ; Vol. 8, No. SEP.
@article{6a3c4a2cb06243f6bbbd2aa504fd7462,
title = "The future is now-prospective study of radiosurgery for more than 4 brain metastases to start in 2018!",
abstract = "Stereotactic radiosurgery (SRS) has replaced whole brain radiotherapy (WBRT) as standard therapy for most patients with four or fewer brain metastases due to improved cognitive outcomes and more favorable health related quality of life (QoL). Whether SRS or WBRT is the optimal radiation modality for patients with five to fifteen brain metastases remains an open question. Efforts are underway to develop prospective evidence to answer this question. One of the planned trials is a Canadian Cancer Trials Group (CCTG)-lead North American intergroup trial. In general cancer treatments must have two basic aims: prolonging and improving QoL. In this vein, the selection of overall survival and QoL metrics as outcomes appear obvious. Potential secondary outcomes are numerous: patient/disease related, treatment related, economic, translational, imaging, and dosimetric. In designing a trial, one must also ponder what is standard WBRT-specifically, whether it should be associated with memantine. With the rapid accrual of an intergroup trial of hippocampal-sparing WBRT, we may find that the standard WBRT regimen changes in the course of planned trials. As up-front radiosurgery is increasingly used for more than 4 brain metastases without high level evidence, we have a window of opportunity to develop high quality evidence which will help guide our future clinical and policy decisions.",
keywords = "Brain metastasis, Clinical trials, Neurocognition, Phase III as topic, Radiosurgery, Whole brain radiation therapy",
author = "David Roberge and Brown, {Paul D.} and Anthony Whitton and Chris O'Callaghan and Anne Leis and Jeffrey Greenspoon and Smith, {Grace Li} and Jennifer Hu and Alan Nichol and Chad Winch and Chan, {Michael D.}",
year = "2018",
month = "9",
day = "13",
doi = "10.3389/fonc.2018.00380",
language = "English (US)",
volume = "8",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "SEP",

}

TY - JOUR

T1 - The future is now-prospective study of radiosurgery for more than 4 brain metastases to start in 2018!

AU - Roberge, David

AU - Brown, Paul D.

AU - Whitton, Anthony

AU - O'Callaghan, Chris

AU - Leis, Anne

AU - Greenspoon, Jeffrey

AU - Smith, Grace Li

AU - Hu, Jennifer

AU - Nichol, Alan

AU - Winch, Chad

AU - Chan, Michael D.

PY - 2018/9/13

Y1 - 2018/9/13

N2 - Stereotactic radiosurgery (SRS) has replaced whole brain radiotherapy (WBRT) as standard therapy for most patients with four or fewer brain metastases due to improved cognitive outcomes and more favorable health related quality of life (QoL). Whether SRS or WBRT is the optimal radiation modality for patients with five to fifteen brain metastases remains an open question. Efforts are underway to develop prospective evidence to answer this question. One of the planned trials is a Canadian Cancer Trials Group (CCTG)-lead North American intergroup trial. In general cancer treatments must have two basic aims: prolonging and improving QoL. In this vein, the selection of overall survival and QoL metrics as outcomes appear obvious. Potential secondary outcomes are numerous: patient/disease related, treatment related, economic, translational, imaging, and dosimetric. In designing a trial, one must also ponder what is standard WBRT-specifically, whether it should be associated with memantine. With the rapid accrual of an intergroup trial of hippocampal-sparing WBRT, we may find that the standard WBRT regimen changes in the course of planned trials. As up-front radiosurgery is increasingly used for more than 4 brain metastases without high level evidence, we have a window of opportunity to develop high quality evidence which will help guide our future clinical and policy decisions.

AB - Stereotactic radiosurgery (SRS) has replaced whole brain radiotherapy (WBRT) as standard therapy for most patients with four or fewer brain metastases due to improved cognitive outcomes and more favorable health related quality of life (QoL). Whether SRS or WBRT is the optimal radiation modality for patients with five to fifteen brain metastases remains an open question. Efforts are underway to develop prospective evidence to answer this question. One of the planned trials is a Canadian Cancer Trials Group (CCTG)-lead North American intergroup trial. In general cancer treatments must have two basic aims: prolonging and improving QoL. In this vein, the selection of overall survival and QoL metrics as outcomes appear obvious. Potential secondary outcomes are numerous: patient/disease related, treatment related, economic, translational, imaging, and dosimetric. In designing a trial, one must also ponder what is standard WBRT-specifically, whether it should be associated with memantine. With the rapid accrual of an intergroup trial of hippocampal-sparing WBRT, we may find that the standard WBRT regimen changes in the course of planned trials. As up-front radiosurgery is increasingly used for more than 4 brain metastases without high level evidence, we have a window of opportunity to develop high quality evidence which will help guide our future clinical and policy decisions.

KW - Brain metastasis

KW - Clinical trials

KW - Neurocognition

KW - Phase III as topic

KW - Radiosurgery

KW - Whole brain radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=85055137106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055137106&partnerID=8YFLogxK

U2 - 10.3389/fonc.2018.00380

DO - 10.3389/fonc.2018.00380

M3 - Review article

AN - SCOPUS:85055137106

VL - 8

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - SEP

M1 - 380

ER -